ADVL1712: A Feasibility Trial of MLN4924 (Pevonedistat, Tak 924) Given in Combination with Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed Myelodysplastic Syndrome
MLN4924 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (1 month to 17 years old)
Sponsor: Children's Oncology Group
Enrolling: Male and Female Patients
IRB Number: AAAS4940
U.S. Govt. ID: NCT03813147
Contact: Luca Szalontay: 212-305-9770 / ls3399@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find the best dose of pevonedistat that can be given safely with chemotherapy in children with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) that has either come back or has not responded to the standard therapy. Pevonedistat works by blocking some of the enzymes that are needed for cell growth.
This study is closed
Investigator
Luca Szalontay, MD
Do You Qualify?
Is your child between 1 month and 17 years of age? Yes No
Does your child have relapsed or refractory AML or relapsed MDS? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Luca Szalontay
ls3399@cumc.columbia.edu
212-305-9770
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE